普瑞巴林市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球普瑞巴林市场价值为 18 亿美元，预计到 2034 年将以 5.1% 的复合年增长率成长，达到 30 亿美元。这种持续上升的趋势反映了对慢性神经系统疾病（包括神经性疼痛、癫痫和广泛性焦虑症 (GAD)）的有效治疗的需求不断增长。普瑞巴林因其抗惊厥和镇痛的双重作用，已成为全球製药领域的基石。医疗保健专业人士越来越多地将其作为阿片类药物的更安全替代品，特别是在长期疼痛管理中。它在医院、零售药局和线上平台的日益普及证明了其治疗的可靠性。无论是在已开发地区还是新兴地区，不断扩大的患者群体、不断提高的健康意识以及医疗保健服务的改善都在加速市场渗透。人们对慢性疼痛状况的认识不断提高，加上全球向非阿片类药物治疗方案的转变，继续为全球製造商和供应商创造有利可图的成长机会。此外，有利的监管框架和医疗保健领域不断增长的投资正在推动製药公司加强在该领域的影响力，推动创新和商业化策略。

普瑞巴林市场主要分为两种剂型：锭剂、胶囊剂和口服液。药片和胶囊仍然是患者和医疗保健提供者的首选，主要是因为它们使用方便且剂量一致。预计该领域的复合年增长率为 5.1%，到 2034 年将达到 23 亿美元。固体剂型带来的便利性对于管理慢性病的患者尤其重要，因为与液体製剂相比，药片和胶囊更容易储存、运输和服用。此外，製药公司不断扩大其产品线，提供不同剂量的产品，从而实现更个人化的治疗方案并提高患者的依从性。

从应用方面来看，普瑞巴林市场分为癫痫、神经性疼痛、广泛性焦虑症和其他用途。其中，神经性疼痛领域预计将以 5.2% 的复合年增长率实现最快增长，到 2034 年将达到 16 亿美元。糖尿病、癌症和老化相关神经损伤发病率的上升正在推动对有效神经性疼痛疗法的需求。医疗保健提供者优先考虑早期诊断和及时干预，而患者则越来越多地寻求传统疼痛缓解方法的可持续替代方案。因此，普瑞巴林作为神经病学的一线治疗选择继续受到青睐。

2024 年美国普瑞巴林市场价值为 7.54 亿美元，预计将维持强劲成长动能。慢性神经病变的激增，加上人们对阿片类药物依赖相关风险的认识提高，推动了这一趋势。普瑞巴林作为非鸦片类止痛药的定位使其成为医生和患者的首选，特别是在治疗糖尿病神经病变和带状疱疹后神经痛等疾病方面。

影响全球普瑞巴林市场格局的知名企业包括 Zydus Lifesciences、Cipla、Teva Pharmaceutical Industries、Aurobindo Pharma、Amneal Pharmaceuticals、Apotex、Dr. Reddy's Laboratories、Torrent Pharmaceuticals、辉瑞、Hikma Pharmaceuticals、Sunaborceuticals、Sunaborceuticals、诺华、Hikma Pharmaceuticals、Sunaborceuticals、Luaborceuticals、AlFator、AlFators、Luaborceuticals。这些公司不断投资研发以增强普瑞巴林的配方。策略合作、收购和扩大生产能力正在帮助产业领导者满足不断增长的全球需求，同时保持竞争力。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 神经性疼痛和癫痫的盛行率不断上升
    • 老年人口不断增加
    • 扩大新适应症的批准
    • 通用版本的可用性不断提高
  • 产业陷阱与挑战
    • 严格的监管要求
    • 滥用和成瘾的风险
• 成长潜力分析
• 监管格局
• 技术格局
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按配方，2021 - 2034 年

• 主要趋势
• 片剂和胶囊
• 口服溶液

第六章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 神经性疼痛
• 癫痫
• 广泛性焦虑症
• 其他应用

第七章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 电子商务

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Alkem Laboratories
• Amneal Pharmaceuticals
• Apotex
• Aurobindo Pharma
• Cipla
• Dr. Reddy's Laboratories
• Hikma Pharmaceuticals
• Lupin
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals
• Viatris
• Zydus Lifesciences

The Global Pregabalin Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 5.1% to reach USD 3 billion by 2034. This consistent upward trajectory reflects the rising demand for effective treatments targeting chronic neurological conditions, including neuropathic pain, epilepsy, and generalized anxiety disorder (GAD). Pregabalin has become a cornerstone in the global pharmaceutical landscape due to its dual action as an anticonvulsant and analgesic. Healthcare professionals are increasingly prescribing it as a safer alternative to opioids, especially in long-term pain management. Its growing acceptance across hospitals, retail pharmacies, and online platforms is a testament to its therapeutic reliability. In both developed and emerging regions, an expanding patient base, rising health awareness, and improvements in healthcare access are accelerating market penetration. Increased awareness around chronic pain conditions, combined with a global shift toward non-opioid treatment options, continues to create lucrative growth opportunities for manufacturers and suppliers worldwide. Additionally, favorable regulatory frameworks and growing investments in the healthcare sector are pushing pharmaceutical companies to strengthen their presence in this space, fueling innovation and commercialization strategies.

The pregabalin market is segmented into two primary formulations: tablets and capsules and oral solutions. Tablets and capsules remain the preferred choice among patients and healthcare providers, primarily because of their ease of use and consistent dosing. This segment is projected to grow at a CAGR of 5.1%, reaching USD 2.3 billion by 2034. The convenience offered by solid dosage forms is especially important for patients managing chronic conditions, as tablets and capsules are easier to store, transport, and consume compared to liquid formulations. Moreover, pharmaceutical companies continue to expand their product lines with varied dosage strengths, enabling more personalized treatment regimens and enhancing patient adherence.

In terms of application, the pregabalin market is categorized into epilepsy, neuropathic pain, generalized anxiety disorder, and other uses. Among these, the neuropathic pain segment is anticipated to record the fastest growth at a CAGR of 5.2%, reaching USD 1.6 billion by 2034. Rising incidences of diabetes, cancer, and aging-related nerve damage are fueling the demand for effective neuropathic pain therapies. Healthcare providers are prioritizing early diagnosis and timely intervention, while patients increasingly seek sustainable alternatives to traditional pain relief methods. As a result, pregabalin continues to gain momentum as a first-line treatment option in neurology.

The U.S. Pregabalin Market was valued at USD 754 million in 2024 and is expected to maintain strong growth momentum. A surge in chronic neuropathic disorders, coupled with heightened awareness about the risks associated with opioid dependency, is driving this trend. Pregabalin's positioning as a non-opioid pain reliever has made it a preferred choice among physicians and patients alike, particularly in managing conditions like diabetic neuropathy and post-herpetic neuralgia.

Prominent players shaping the global pregabalin market landscape include Zydus Lifesciences, Cipla, Teva Pharmaceutical Industries, Aurobindo Pharma, Amneal Pharmaceuticals, Apotex, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Sun Pharmaceutical Industries, Novartis, Alkem Laboratories, Lupin, and Viatris. These companies are consistently investing in research and development to enhance pregabalin formulations. Strategic collaborations, acquisitions, and expanded production capacities are helping industry leaders meet rising global demand while staying competitive.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neuropathic pain and epilepsy
    • 3.2.1.2 Growing geriatric population
    • 3.2.1.3 Expanding approval for new indications
    • 3.2.1.4 Increasing availability of generic versions
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Risk of misuse and addiction
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Formulation, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Tablets and capsules
• 5.3 Oral solution

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Neuropathic pain
• 6.3 Epilepsy
• 6.4 Generalized anxiety disorder
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Alkem Laboratories
• 9.2 Amneal Pharmaceuticals
• 9.3 Apotex
• 9.4 Aurobindo Pharma
• 9.5 Cipla
• 9.6 Dr. Reddy’s Laboratories
• 9.7 Hikma Pharmaceuticals
• 9.8 Lupin
• 9.9 Novartis
• 9.10 Pfizer
• 9.11 Sun Pharmaceutical Industries
• 9.12 Teva Pharmaceutical Industries
• 9.13 Torrent Pharmaceuticals
• 9.14 Viatris
• 9.15 Zydus Lifesciences